Horizon Therapeutics Public Limited Co (fka HZNP)

[surf1944]

7:31AM Horizon Pharma and Mundipharma sign exclusive agreement to commercialize LODOTRA in the Middle East and Africa (HZNP) 4.86 : Co announced that its Swiss subsidiary has signed an exclusive agreement with Mundipharma for the commercialization and distribution of LODOTRA in the Middle East and African Region. LODOTRA, a delayed-release formulation of prednisone specifically designed to deliver the active drug at the most physiologically efficient time, is approved in the U.S. under the trade name RAYOS and in over thirty other countries to treat moderate to severe active Rheumatoid Arthritis when accompanied by morning stiffness.

Under the agreement, Mundipharma will have rights to commercialize LODOTRA in fifty-five additional countries. Mundipharma will utilize a combination of company resources and partnerships to support LODOTRA commercialization in the licensed regions.